Impaired Antibody Response Following the Second Dose of the BNT162b2 Vaccine in Patients With Myeloproliferative Neoplasms Receiving Ruxolitinib

Data on the effect of ruxolitinib on antibody response to severe acute respiratory coronavirus 2 (SARS-CoV-2) vaccination in patients with myeloproliferative neoplasms (MPN) is lacking. We prospectively evaluated anti-spike-receptor binding domain antibody (anti-S Ab) levels after the second dose of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Daisuke, Terao, Toshiki, Miura, Daisuke, Narita, Kentaro, Fukumoto, Ami, Kuzume, Ayumi, Kamura, Yuya, Tabata, Rikako, Tsushima, Takafumi, Takeuchi, Masami, Hosoki, Takaaki, Matsue, Kosei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990027/
https://www.ncbi.nlm.nih.gov/pubmed/35402455
http://dx.doi.org/10.3389/fmed.2022.826537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990027/
https://www.ncbi.nlm.nih.gov/pubmed/35402455
http://dx.doi.org/10.3389/fmed.2022.826537

Ejemplares similares